Oxford BioDynamics occupies an unusual corner of diagnostics. Where most molecular tests read the DNA sequence itself, the AIM-listed company reads the genome's three-dimensional architecture — how chromosomes fold and loop — and turns those patterns into blood tests. The science is distinctive and the clinical questions genuinely significant. Yet the company enters mid-2026 with rising but still slender revenue, persistent losses, and an explicit warning that further funding is required within months.

The Quick Version

  • Oxford BioDynamics (AIM: OBD) commercialises blood tests built on its EpiSwitch chromosome-conformation, or 3D-genomics, platform.
  • EpiSwitch PSE prostate screening drove test orders up 126% year on year in the half to 31 March 2026, though total revenue remained modest at £687,000.
  • EpiSwitch CiRT, for immune checkpoint inhibitor selection, reported interim clinical-utility data; broader uptake is tied to guideline inclusion.
  • Cash stood at £2.51m at 31 March 2026 and £1.38m by 31 May 2026, with directors flagging a need for further funding by late August 2026.
  • The investment case turns on converting validation into reimbursed clinical adoption before the balance sheet forces further dilution.

What Oxford BioDynamics Actually Does

EpiSwitch measures chromosome conformations — how DNA folds inside the nucleus — to identify regulatory signatures associated with disease, arguing these change systemically and early in disease and can be detected in a routine blood sample. Discovery uses a chromosome-conformation-capture approach paired with a high-density microarray screening around a million potential regulatory interactions; validated signatures are translated into a smaller panel read on standard qPCR instruments.

PSE: Genuine Order Momentum

EpiSwitch PSE helps clinicians decide which men with elevated risk factors genuinely need a prostate biopsy. Orders rose to 1,788 from 791 a year earlier — a 126% increase — with cumulative volumes passing 5,000 tests since the 2023 launch. A 2025 real-world study in the journal Cancers examined how the test influenced biopsy decisions at a single US urology centre — best characterised as retrospective real-world evidence rather than a prospective outcomes trial, with the authors acknowledging selection effects.

CiRT: Guideline Inclusion Is the Next Hurdle

EpiSwitch CiRT aims to predict response to immune checkpoint inhibitor therapy. Interim results from the PROWES study, published in Cancers, reported clinical utility across solid tumours, with the test said to have influenced treatment choices in a majority of assessed cases. The company intends to apply for inclusion in National Comprehensive Cancer Network (NCCN) guidelines — a step regarded as important for broader adoption and reimbursement.

The Funding Deadline

Revenue for the six months to 31 March 2026 was £687,000, up from £587,000 a year earlier, sales overwhelmingly from clinical tests. The operating loss narrowed to £4.68m from £5.88m — tighter cost control, but still substantially loss-making relative to revenue.

Cash stood at £2.51m at 31 March 2026 and had fallen to £1.38m by 31 May 2026. The company stated additional funding would be required by late August 2026, with going-concern contingent on securing it — a material uncertainty. This follows a November 2025 equity raise bringing in roughly £7m gross (about £6.3m net) via a placing, subscription and retail offer, already substantially consumed.

New Leadership

Richard Compton — previously with Oxford Nanopore and Illumina, and an adviser to OBD — was appointed CEO with effect from June 2026, arriving at a pivotal moment for the funding and commercial strategy.

Risks Worth Weighing

Financial risk is foremost — the company has explicitly flagged a need for further funding by late August 2026, and going concern rests on securing it; failure, or a raise on unfavourable terms, would be highly consequential. Commercially, revenue remains small and concentrated in a single test. Reimbursement risk is material without broad payer coverage and guideline endorsement. Much of the supporting data is from validation and real-world studies rather than large prospective outcome trials — validation performance isn't the same as proven clinical benefit.

What to Watch Next

A resolution of the funding position, ideally on manageable terms — the most immediate overhang. Formal application for, and progress toward, NCCN guideline inclusion for CiRT. Evidence of payer reimbursement wins for PSE. Continued strong growth in PSE test volumes and new peer-reviewed publications.